On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

“Without appropriate preparation and intervention, patients may experience significant hypoxemia in flight, which can lead to ...

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

A recent study reveals that COPD, or Smokers' Disease, is impacting younger individuals. Doctors in Delhi are observing a ...

While there has been progress against chronic disease, the U.S. has been backsliding against big killers like heart disease.

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

A major global study published in The Lancet has found that while deaths from chronic diseases such as cancer, heart disease, ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...